Osteocalcin promoter-based toxic gene therapy for the treatment

Details Osteocalcin promoter-based toxic gene therapy for the treatment Osteocalcin promoter-based toxic gene therapy for the treatment

1997-01-21

1998-06-30

Feisee, Lila

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Virus or bacteriophage

514 44, 4353201, 435 712, 424 92, A61K 4800, A01N 6300, C12P 2104, C12N 1500

Patent

active

057729930

ABSTRACT:
A recombinant adenovirus Ad-OC-TK was constructed, with cell specific gene expression, which contains osteocalcin (OC) promoter that drives the expression of herpes simplex virus thymidine kinase (TK); the addition of acyclovir (ACV), a pro-drug for the inhibition of cell proliferation, to Ad-OC-TK resulted in the induction of osteoblast-specific cell death in vitro. The Ad-OC-TK virus plus ACV treatment is highly selective in blocking the growth of both murine and human osteosarcoma cell lines in vitro and murine osteosarcoma in vivo.

REFERENCES:
Su et al Human Gene Therapy (1996) Mar. 1 7(4) 463-70.
Henderson et al WO 9701358 Jan. 16, 1997.
Ko et al Cancer Res Oct. 15, 1996, 56(20) pp. 4614-4619.

Affiliated with

Also associated with

Rating

Osteocalcin promoter-based toxic gene therapy for the treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Osteocalcin promoter-based toxic gene therapy for the treatment , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Osteocalcin promoter-based toxic gene therapy for the treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1856174